Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nonprofit To Subpoena Pfizer Documents Related To Viagra Online Distribution

This article was originally published in The Pink Sheet Daily

Executive Summary

Subpoena is part of the discovery process in a lawsuit in which the AIDS Healthcare Foundation alleges improper Viagra marketing practices.

You may also be interested in...



Ball Drops On Pfizer's New Year's Eve-Themed Ads For Viagra

AIDS Healthcare Foundation urges Pfizer to curb "irresponsible" advertising for its erectile dysfunction drug.

Viagra "Wild Thing" Ads Too Wild For FDA; Pfizer Will Pull Them

FDA declares that the ads, featuring a man with blue horns, cross the line and cannot be considered unbranded "reminder" ads. Pfizer says it will discuss FDA's concerns before deciding whether and how to resume the campaign.

Celgene To Submit Revlimid Phase III Special Protocol Assessment For CLL To FDA Shortly

Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS065062

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel